Clinical trials: Non Alcoholic Fatty Liver
NASH (Non-alcoholic Steato-hepatitis)
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
- Trial name
- NCT01406704
- Testing
- Rosiglitazone, alpha-lipoic acid, Rosiglitazone/alpha-lipoic acid
- Volunteers
- 26 people
- Sponsor
- Seoul St. Mary's Hospital
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates
Nonalcoholic Liver disease (NAFLD) is known to be caused by deposition of fat in the liver. The impact of NAFLD on bariatric surgery is of great concern.
- Trial name
- NCT00887393
- Testing
- low carbohydrate diet, low-fat diet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Michigan
Liver Diseases, Liver Cirrhosis
Palliative Care for Non-Malignant Diseases (COMPASS Trial)
The purpose of this study is to evaluate, through a randomized controlled trial, the impact of integrated comprehensive palliative care services on time to first hospital readmission and other hospital utilization outcomes…
- Conditions
- Liver Diseases, Liver Cirrhosis, NASH (Non-Alcoholic Steatohepatitis)
- Trial name
- COMPASS (NCT03022630)
- Testing
- Comprehensive Palliative Care services, Usual hepatic care
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Vanderbilt University Medical Center
Non-alcoholic Steatohepatitis
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.
- Trial name
- NCT05668936
- Testing
- Cotadutide, Moxifloxacin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-alcoholic Fatty Liver Disease
Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease
The study searched for answers to two questions: 1-What are the plasma betatrophin levels in subjects with non-alcoholic fatty liver disease and healthy controls. 2.
- Trial name
- NCT02176811
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Nonalcoholic Fatty Liver Disease
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal…
- Trial name
- NCT06044467
- Testing
- Anti-human CCL24 monoclonal antibody (CM-101) - Part One, Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- ChemomAb Ltd.
Non-alcoholic Fatty Liver Disease
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver.
- Trial name
- NCT02006498
- Testing
- Sillymarin
- Where
- Malaysia
- Volunteers
- 99 people
- Sponsor
- University of Malaya
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
Effects of Wheat-based diet vs. ATI-free diet on NASH
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2, Hyperlipidemias
- Trial name
- NASH-ATI (NCT04066400)
- Testing
- Nutritional Intervention
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Johannes Gutenberg University Mainz
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.
The spectrum of NAFLD as emerging epidemic ranges from steatosis to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Disease progression is poorly understood and treatment options are limited.
- Trial name
- NCT01696487
- Testing
- High oral Fructose challenge (150g per day for 28 days)
- Where
- Austria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non Alcoholic Fatty Liver Disease
Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
Investigation the Effects of Different Doses of SAMe in Subjects with Nonalcoholic Fatty Liver Disease and non-treated matched healthy volunteers as control group
- Trial name
- EXPO (NCT01754714)
- Testing
- SAMe 1000 mg, SAMe 1500 mg, SAMe 2000 mg
- Where
- 32 sites in France, Germany and 2 more
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Abbott
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
The Liver Health Study for Patients with NAFLD
The study will investigate whether the level of fat stored in the liver is related to the liver's ability to burn fat.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
- Trial name
- NCT03151798
- Testing
- Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- University of Missouri-Columbia
Non-Alcoholic Fatty Liver Disease
Biological Adaptations of Strength Training.
A two-trial repeated measures design will be employed in this investigation. Both the control trial and the exercise trial will last for 3 months.
- Trial name
- NCT04098484
- Testing
- Control Trial, Exercise Trial
- Where
- Greece
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Democritus University of Thrace
Diabetes Mellitus, Type 2, Overweight and Obesity
The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 Diabetes
The primary aim of this randomized cross-over intervention study is to investigate the effect of four weeks of intermittent carbohydrate restriction (alternating between two days of normal dietary intake and two days of…
- Conditions
- Diabetes Mellitus, Type 2, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- INTERCARB (NCT06144593)
- Testing
- Dietary macronutrient composition
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Hvidovre University Hospital
Fatty Liver, Nonalcoholic
Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake
honey is a natural functional food used in control cardiovascular risk factors but its effect on fatty liver is not investigated
- Trial name
- NCT06596109
- Testing
- honey intake and lifestyle changes, lifestyle changes
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Liver Diseases
Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to see how effective the investigators' optimized magnetic resonance spectroscopy (MRS) sequence in quantifying hepatic triglyceride content (HTGC) to enhance MRS as a diagnostic tool in non-alcohol…
- Trial name
- NAFLD (NCT00940537)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Fatty Liver Disease
SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
Obesity is closely associated with an increased risk of cardiomyopathy because of the high metabolic activity of excessive fat while effective treatment of obesity-related cardiomyopathy is currently unsolved.
- Trial name
- NCT05764811
- Testing
- Canagliflozin 100mg
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Cheng-Kung University Hospital
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04389593
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
NAFLD, NASH - Nonalcoholic Steatohepatitis
Splanchnic and Systemic VLDL-TG and FFA Balance
To determine differences between NAFLD and NASH subjects with respect to hepatic FA metabolism (uptake, oxidation, and re-esterification) and hepatic VLDL-TG secretion and peripheral kinetics (oxidation and tissue storage).
- Trial name
- NCT04292977
- Where
- Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
The overall goal of this collaborative research program is to develop, validate and translate advanced quantitative magnetic resonance (MR) biomarkers of obesity-associated non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NAFLD (NCT03674528)
- Testing
- Magnetic Resonance Elastography (MRE), Liver biopsy
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.